Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
4Customers
3Debt Items
5Related Chains
Source-Backed Evidence Depth
CNBX Pharmaceuticals Inc. (CNBX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
5Distinct source URLs
6High confidence
0.780Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
CNBX Pharmaceuticals Inc. Suppliers
Ticker
Name
Confidence
Evidence
3I-L-P
3I-L-P
92%
On March 10th, 2026, the Company executed a non-convertible Promissory Note with 3i L.P., a Delaware Limited Partnership for the amount of $45,000.
INSTITUTIONAL-INVESTOR
INSTITUTIONAL-INVESTOR
92%
The Institutional Investor agreed to forbear until June 1, 2026 from taking any action against the Company with respect to unpaid amounts owed and to waive certain other defaults under the Note and o…
PURISYS
PURISYS
90%
Additionally, in view of our upcoming submission of a pre-IND meeting request with the FDA, the Company may enter a new agreement with Purisys, a supplier of GMP (Good Manufacturing Practice) grade A…
Reciprocal relationship from INM graph: Reciprocal relationship from CNBX graph: Reciprocal relationship from INM graph: Reciprocal relationship from CNBX graph: Reciprocal relationship from INM grap…
Reciprocal relationship from PMCB graph: Reciprocal relationship from CNBX graph: Reciprocal relationship from PMCB graph: Reciprocal relationship from CNBX graph: Reciprocal relationship from PMCB g…
CNBX Pharmaceuticals Inc. Customers
Ticker
Name
Confidence
Evidence
AMERICAN-MINING-COMPANY
AMERICAN-MINING-COMPANY
62%
to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. Recent Sales of Unregiste…
CANNABICS-PHARMACEUTICAL-INC
CANNABICS-PHARMACEUTICAL-INC
62%
hare-based payments and the valuation allowance on deferred tax assets. Principles of Consolidation The consolidated financial statements include the accounts of Cannabics Pharmaceutical Inc. and its…
G-R-I-N-ULTRA-LTD
G-R-I-N-ULTRA-LTD
62%
hare-based payments and the valuation allowance on deferred tax assets. Principles of Consolidation The consolidated financial statements include the accounts of Cannabics Pharmaceutical Inc. and its…
THRUST-ENERGY-CORP
THRUST-ENERGY-CORP
62%
to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. Recent Sales of Unregiste…
CNBX Pharmaceuticals Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CNBX-DEBT-8734
Warrants outstanding: 675123
90%
xbrl warrant detail from xbrl 2021-08-31.
CNBX-DEBT
Debt stack $120,000
90%
Market cache reports total debt of $120,000.
CNBX-DEBT-8735
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2026-02-28.
CNBX Pharmaceuticals Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for CNBX Pharmaceuticals Inc..
CNBX Pharmaceuticals Inc. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for CNBX Pharmaceuticals Inc..
CNBX Pharmaceuticals Inc. Extended Supply Chain Network
